Stephen Mason

Stephen Mason

Dr. Mason has been involved in drug discovery research for the past 19 years. He recently joined CaroGen Corp. as Executive Director, Discovery, to help advance a platform technology of Virus-like Vesicle (VLV) to develop therapeutic vaccines for HBV, oncology, and other indications. Since 2016, he has been a consultant in various capacities for small biotechs and potential start-up companies. From 2010 to 2015, he was Director, Discovery Virology at Bristol-Myers Squibb, leading research efforts toward remission/eradication of HIV-1 and HBV. Much of the focus of this work was on immune-modulatory mechanisms including PD-1/PD-L1. Under his guidance, anti-PD-L1 antibodies were tested in advanced animal disease models for both HIV-1 and HBV as well as in human clinical trials for HIV-1.

From 1998-2010, Dr. Mason was at Boehringer-Ingelheim (Canada) Ltd., where he led several drug discovery teams to find new antiretrovirals against HIV-1 targets including capsid and gag, integrase, reverse transcriptase, entry, vif and others. He also initiated research efforts toward HIV-1 remission/eradication at BI prior to moving to BMS. Early in his tenure at BI, he was involved in the discovery of novel inhibitors against Respiratory Syncytial Virus (RSV) RNA-dependent RNA polymerase and HIV-1 integrase. Prior to working in the pharmaceutical industry, Dr. Mason received his Ph.D. from the University of Toronto working on transcriptional antitermination. His post-doctoral studies were performed at University of Toronto and in Heidelberg, Germany, at the German Cancer Research Center (DKFZ) working on various aspects of transcriptional regulation of host RNA polymerase I and II. He is an inventor on 3 patents or patent applications and co-author of more than 30 peer reviewed publications.